USPTO serial 79421230
HIRUNDO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 24, 2026
- Examiner
- SOUDERS, MICHAEL J
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HIRUNDO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for industrial purposes and chemical preparations for scientific purposes; chemical reagents for scientific purposes in the field of molecular biology; bacterial preparations other than for medical or veterinary use; enzymes and enzyme preparations for industrial use; chemical preparations for analyses in laboratories for scientific use, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes, for use in the research and development and production of drugs, medicinal and pharmaceutical preparations; chemical additives for use in the manufacturing of pharmaceuticals | ACTIVE | — |
| 005 | Pharmaceutical preparations and substances in the field of gynecology and women's health, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; medicinal preparations for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; medicines for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; biochemical medicines for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; pharmaceutical preparations for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, Inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions for use in the field of gynecology and female health; estrogen preparations for therapeutic purposes; pharmaceutical preparations containing estrogen for the treatment and prevention of hormonal dysfunction and menopausal symptoms, conditions and disorders, endometriosis, noninflammatory disorders of female genital tract, inflammatory diseases of female pelvic organs, disorders of breast, breast cancer, ovarian cancer, endometrial cancer, vaginal cancer, cervical cancer, fallopian tube cancer, polycystic ovarian syndrome, neoplasm of uncertain or unknown behaviour of the uterus and ovary, menopause, infertility, urinary tract, contraception, uterine fibroids and postprocedural pelvic peritoneal adhesions; pharmaceutical preparations for the treatment of female hormonal dysfunction; pharmaceutical preparations for use in hormone replacement therapy; pharmaceutical preparations for the treatment of menopausal symptoms, conditions and disorders | ACTIVE | — |
| 035 | Market research and business analysis services; business marketing consulting services in the field of pharmaceutical, biotechnology, biochemical, medical device and diagnostics industries; market analysis; providing business information and data processing services in the field of pharmaceutical, biotechnology, biochemical medical device, and diagnostics industries; compilation of statistics for business or commercial purposes in the field of biochemical medical devices | ACTIVE | — |
| 042 | Scientific, clinical surgery, medical and life-science research; research and development in the field of biotechnology and biochemistry; research and development in the field of pharmaceuticals, biopharmaceuticals, medical devices, and medical diagnostics; research relating to molecular sciences; research and development in the field of drug development; testing, analysis, and evaluation of pharmaceutical and biochemical products, especially for use in medicines; research and development of medicines; testing of pharmaceuticals; biotechnology research and development services; product development involving pharmaceutical products; medical and scientific research, namely, conducting clinical trials as part of the research and development of pharmaceuticals and medicines; clinical research in the field of production of chemicals for pharmaceutical use, pharmaceuticals, medical devices and medical diagnostics; scientific research, namely, providing analysis of statistical data in the field of biotechnology; scientific research, namely, providing analysis of statistical data in the field of biotechnological diagnostics industries | ACTIVE | — |
| 044 | Medical services; providing medical advice in the field of efficacy of pharmaceuticals; provision of medical data relating to the use of pharmaceuticals; medical information online and on the internet relating to products, solutions and pharmaceutical and medical advances; medical information online and on the internet about products, solutions, pharmaceutical or medical advances; providing medical research information in the field of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by B.C.I. Pharma
- Other trademarks owned by B.C.I. Pharma
- Other trademarks owned by Daphne Vervaet
- Other trademarks owned by Hirundo Biosciences
- Other trademarks owned by Hirundo Biosciences
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named HIRUNDO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 15, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 24, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 9, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 9, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 1, 2026 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Aug 31, 2026 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Jun 24, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 24, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 24, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 27, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Feb 26, 2026 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 27, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 27, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 21, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 2, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 2, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 2, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 2, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 2, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 2, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 2, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 2, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 2, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 2, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 2, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 2, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 30, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 30, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 30, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 14, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 14, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 30, 2025 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| May 22, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 21, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 21, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 11, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 11, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 10, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |